×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PHAT – phathom pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PHAT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/8
06:19 am
phat
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
High
Report
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
11/7
08:00 am
phat
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Low
Report
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/6
07:34 am
phat
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For [Yahoo! Finance]
Low
Report
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For [Yahoo! Finance]
11/4
08:00 am
phat
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
11/1
10:08 am
phat
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96% [Yahoo! Finance]
Medium
Report
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96% [Yahoo! Finance]
10/28
08:00 am
phat
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
Medium
Report
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
10/27
12:00 pm
phat
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
High
Report
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
9/27
08:44 am
phat
Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges [Seeking Alpha]
Low
Report
Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
08:00 am
PHAT
phathom pharmaceuticals, inc.
BEAT
Report
5.7%
phathom pharmaceuticals, inc.
8/8/2024
08:00 am
PHAT
phathom pharmaceuticals, inc.
BEAT
Report
14.1%
phathom pharmaceuticals, inc.
5/9/2024
08:00 am
PHAT
phathom pharmaceuticals, inc.
BEAT
Report
-0.1%
phathom pharmaceuticals, inc.
3/7/2024
08:00 am
PHAT
phathom pharmaceuticals, inc.
MISS
Report
-6.6%
phathom pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
11:47 am
phat
Form SC 13G Phathom Pharmaceuticals, Filed by: BlackRock, Inc.
High
Report
Form SC 13G Phathom Pharmaceuticals, Filed by: BlackRock, Inc.
11/7
04:05 pm
phat
Form 10-Q Phathom Pharmaceuticals, For: Sep 30
Medium
Report
Form 10-Q Phathom Pharmaceuticals, For: Sep 30
11/7
08:06 am
phat
Form 8-K Phathom Pharmaceuticals, For: Nov 07
Low
Report
Form 8-K Phathom Pharmaceuticals, For: Nov 07
11/5
04:12 pm
phat
Form SCHEDULE 13G/A Phathom Pharmaceuticals, Filed by: PRUDENTIAL FINANCIAL INC
Low
Report
Form SCHEDULE 13G/A Phathom Pharmaceuticals, Filed by: PRUDENTIAL FINANCIAL INC
11/5
03:33 pm
phat
Form SCHEDULE 13G Phathom Pharmaceuticals, Filed by: PRUDENTIAL FINANCIAL INC
Low
Report
Form SCHEDULE 13G Phathom Pharmaceuticals, Filed by: PRUDENTIAL FINANCIAL INC
11/4
11:21 am
phat
Form SC 13G Phathom Pharmaceuticals, Filed by: JENNISON ASSOCIATES LLC
Low
Report
Form SC 13G Phathom Pharmaceuticals, Filed by: JENNISON ASSOCIATES LLC
10/21
04:13 pm
phat
Form SC 13G Phathom Pharmaceuticals, Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G Phathom Pharmaceuticals, Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/3
Form 4 Phathom Pharmaceuticals, For: Apr 01 Filed by: Kolchinsky Peter
13.1%
2/14 Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P. 12.3%
12/23 Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection 11.1%
1/6 Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer 9.6%
10/24 Form S-1MEF Phathom Pharmaceuticals, 9.3%
1/27 Form SC 13D/A Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD 6.9%
12/12 Form 3 Phathom Pharmaceuticals, For: Dec 02 Filed by: Parikh Asit 4.7%
4/9 Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference 2.6%
11/19 Phathom Pharmaceuticals (NASDAQ: PHAT) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 2.4%
11/25 Q3/2019 9/30/2019 EPS -9.300 ZacksConsensus N/A ActVsEst N/A - N/A 2.3%
2/14 Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P. 12.3%
12/23 Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection 11.1%
1/6 Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer 9.6%
10/24 Form S-1MEF Phathom Pharmaceuticals, 9.3%
1/27 Form SC 13D/A Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD 6.9%
12/12 Form 3 Phathom Pharmaceuticals, For: Dec 02 Filed by: Parikh Asit 4.7%
4/9 Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference 2.6%
11/19 Phathom Pharmaceuticals (NASDAQ: PHAT) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 2.4%
11/25 Q3/2019 9/30/2019 EPS -9.300 ZacksConsensus N/A ActVsEst N/A - N/A 2.3%
TOP News Decliners
3/17
Form 8-K Phathom Pharmaceuticals, For: Mar 11
-10.0%
3/20 Phathom Pharmaceuticals (NASDAQ: PHAT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -3.8%
10/26 Phathom Pharmaceuticals goes public [Reuters] -3.5%
3/19 Form 3 Phathom Pharmaceuticals, For: Mar 17 Filed by: Stenhouse Mark -3.3%
3/31 Form 4 Phathom Pharmaceuticals, For: Mar 27 Filed by: Kolchinsky Peter -2.9%
2/6 Form 3/A Phathom Pharmaceuticals, For: Feb 06 Filed by: Kolchinsky Peter -2.5%
11/6 Form SC 13D Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD -2.1%
10/28 Form S-8 Phathom Pharmaceuticals, -1.1%
2/14 Form SC 13G Phathom Pharmaceuticals, Filed by: JANUS HENDERSON GROUP PLC -1.1%
12/2 Form 8-K Phathom Pharmaceuticals, For: Nov 30 -0.9%
3/20 Phathom Pharmaceuticals (NASDAQ: PHAT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -3.8%
10/26 Phathom Pharmaceuticals goes public [Reuters] -3.5%
3/19 Form 3 Phathom Pharmaceuticals, For: Mar 17 Filed by: Stenhouse Mark -3.3%
3/31 Form 4 Phathom Pharmaceuticals, For: Mar 27 Filed by: Kolchinsky Peter -2.9%
2/6 Form 3/A Phathom Pharmaceuticals, For: Feb 06 Filed by: Kolchinsky Peter -2.5%
11/6 Form SC 13D Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD -2.1%
10/28 Form S-8 Phathom Pharmaceuticals, -1.1%
2/14 Form SC 13G Phathom Pharmaceuticals, Filed by: JANUS HENDERSON GROUP PLC -1.1%
12/2 Form 8-K Phathom Pharmaceuticals, For: Nov 30 -0.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: